Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Business / Clearmind Medicine Secures US Patents
Business patent grant

Clearmind Medicine Secures US Patents

Analysis based on 8 articles · First reported Jun 18, 2026 · Last updated Jun 29, 2026

Sentiment
60
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The granting of two U.S. patents to Clearmind Medicine is expected to positively impact the company's stock price due to strengthened intellectual property and validation of its therapeutic approach. This could lead to increased investor confidence and potential for future commercial success in the biotechnology sector. The patents cover MEAI (5-methoxy-2-aminoindane) molecule and related 2-aminoindan derivatives for regulating binge behaviors.

biotechnology pharmaceuticals
Event Summary

Clearmind Medicine Inc., a clinical-stage biotech company, announced the grant of two U.S. Patents, No. 12,350,242 and No. 12,357,590, by the United States — United States Patent and Trademark Office. Both patents are titled 'BINGE BEHAVIOR REGULATORS' and cover the MEAI (5-methoxy-2-aminoindane) molecule and related 2-aminoindan derivatives for regulating binge behaviors, including excessive drinking, eating, and other compulsive disorders. These grants significantly strengthen Clearmind Medicine's global intellectual property portfolio and are expected to advance its clinical programs for binge-related disorders, such as alcohol use disorder. Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, emphasized the importance of these patents in reinforcing the company's leadership in psychedelic-based therapies.

Entities Involved
stock
Clearmind Medicine
Clearmind Medicine received two U.S. patents, strengthening its intellectual property portfolio for binge behavior regulators and advancing its clinical programs for related disorders. This enhances the company's market position and potential for commercialization.
Importance 100.0 Sentiment 70.0
govactor
United States — United States Patent and Trademark Office
The United States — United States Patent and Trademark Office granted two patents to Clearmind Medicine, validating the company's intellectual property in the field of binge behavior regulators.
Importance 70.0 Sentiment 0.0
per
Adi Zuloff-Shani
Adi Zuloff-Shani, CEO of Clearmind Medicine, commented on the significance of the patent grants, highlighting their role in advancing clinical programs and reinforcing the company's leadership in psychedelic-based therapies.
Importance 40.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.